دورية أكاديمية
أعرض في EDS

Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.

التفاصيل البيبلوغرافية
العنوان: Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.
المؤلفون: Herrera-Rodriguez J; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Signorazzi A; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Holtrop M; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., de Vries-Idema J; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Huckriede A; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: a.l.w.huckriede@umcg.nl.
المصدر: Vaccine [Vaccine] 2019 Mar 14; Vol. 37 (12), pp. 1630-1637. Date of Electronic Publication: 2019 Feb 11.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
أسماء مطبوعة: Publication: Amsterdam, The Netherlands : Elsevier Science
Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
مواضيع طبية MeSH: Virus Inactivation*, Influenza A virus/*immunology , Influenza Vaccines/*immunology , Vaccines, Inactivated/*immunology , Virion/*immunology, Animals ; Cell Line ; Formaldehyde/pharmacology ; Hemagglutinin Glycoproteins, Influenza Virus/immunology ; Humans ; Influenza A virus/drug effects ; Influenza A virus/isolation & purification ; Virion/drug effects ; Virion/isolation & purification
مستخلص: The vast majority of commercially available inactivated influenza vaccines are produced from egg-grown or cell-grown live influenza virus. The first step in the production process is virus inactivation with β-propiolactone (BPL) or formaldehyde (FA). Recommendations for production of inactivated vaccines merely define the maximal concentration for both reagents, leaving the optimization of the process to the manufacturers. We assessed the effect of inactivation with BPL and FA on 5 different influenza virus strains. The properties of the viral formulation, such as successful inactivation, preservation of hemagglutinin (HA) binding ability, fusion capacity and the potential to stimulate a Toll-like receptor 7 (TLR7) reporter cell line were then assessed and compared to the properties of the untreated virus. Inactivation with BPL resulted in undetectable infectivity levels, while FA-treated virus retained very low infectious titers. Hemagglutination and fusion ability were highly affected by those treatments that conferred higher inactivation, with BPL-treated virus binding and fusing at a lower degree compared to FA-inactivated samples. On the other hand, BPL-inactivated virus induced higher levels of activation of TLR7 than FA-inactivated virus. The alterations caused by BPL or FA treatments were virus strain dependent. This data shows that the inactivation procedures should be tailored on the virus strain, and that many other elements beside the concentration of the inactivating agent, such as incubation time and temperature, buffer and virus concentration, have to be defined to achieve a functional product.
(Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
References: Vaccine. 1985 Sep;3(3 Suppl):215-8. (PMID: 4060851)
Avian Dis. 1991 Jul-Sep;35(3):505-14. (PMID: 1835374)
Influenza Other Respir Viruses. 2008 Mar;2(2):41-51. (PMID: 19453471)
Proteomics. 2013 Dec;13(23-24):3537-47. (PMID: 24123778)
Acta Microbiol Immunol Hung. 2018 Jun 1;65(2):163-171. (PMID: 29685054)
Vaccine. 1991 Jun;9(6):398-402. (PMID: 1887669)
Nat Rev Drug Discov. 2015 Mar;14(3):167-82. (PMID: 25722244)
PLoS One. 2012;7(1):e30898. (PMID: 22303469)
Lancet. 2003 Nov 22;362(9397):1733-45. (PMID: 14643124)
Viruses. 2015 Feb 10;7(2):666-79. (PMID: 25674771)
Dev Biol Stand. 1993;81:103-7. (PMID: 8174792)
Nature. 1981 Oct 8;293(5832):479-80. (PMID: 6273731)
Int J Mol Sci. 2017 Mar 27;18(4):. (PMID: 28346372)
Zoonoses Public Health. 2007;54(2):51-68. (PMID: 17348909)
PLoS Pathog. 2008 Aug 29;4(8):e1000138. (PMID: 18769719)
Vaccine. 2012 Oct 5;30(45):6501-7. (PMID: 22841974)
J Immunol. 1999 Nov 1;163(9):4673-82. (PMID: 10528164)
J Biol Chem. 2011 Oct 21;286(42):36198-214. (PMID: 21868382)
Anal Biochem. 1977 Dec;83(2):346-56. (PMID: 603028)
Scand J Immunol. 2005 Jul;62(1):36-44. (PMID: 16092921)
Bioconjug Chem. 2006 May-Jun;17(3):815-22. (PMID: 16704222)
Biochim Biophys Acta. 2014 Jan;1838(1 Pt B):355-63. (PMID: 24140008)
J Virol. 2015 Jan;89(1):350-60. (PMID: 25320308)
Vaccine. 2010 Dec 6;28(52):8280-7. (PMID: 20965298)
PLoS One. 2016 Mar 09;11(3):e0150700. (PMID: 26959983)
Clin Microbiol Rev. 2013 Jul;26(3):476-92. (PMID: 23824369)
Vet Microbiol. 1993 Nov;37(3-4):253-62. (PMID: 8116186)
Rev Sci Tech. 2009 Apr;28(1):187-202. (PMID: 19618626)
Langmuir. 2011 Nov 15;27(22):13675-83. (PMID: 21981550)
J Gen Virol. 2010 Jun;91(Pt 6):1450-60. (PMID: 20147516)
Nat Immunol. 2004 Oct;5(10):987-95. (PMID: 15454922)
J Clin Microbiol. 2010 Mar;48(3):928-40. (PMID: 20089763)
Appl Microbiol. 1970 Feb;19(2):290-4. (PMID: 5437304)
J Virol Methods. 2014 Oct;207:232-7. (PMID: 25025814)
Adv Exp Med Biol. 2012;726:201-21. (PMID: 22297515)
J Virol Methods. 2015 Sep 15;222:28-33. (PMID: 25997377)
Nat Immunol. 2002 Feb;3(2):196-200. (PMID: 11812998)
Vaccine. 2011 Jun 10;29(26):4345-52. (PMID: 21514345)
Proc Natl Acad Sci U S A. 1970 Apr;65(4):1105-12. (PMID: 5266149)
World J Virol. 2016 May 12;5(2):85-6. (PMID: 27175354)
J Virol Methods. 2004 Oct;121(1):85-91. (PMID: 15350737)
فهرسة مساهمة: Keywords: Formaldehyde; Inactivation; Influenza; Vaccine; β-propiolactone
المشرفين على المادة: 0 (Hemagglutinin Glycoproteins, Influenza Virus)
0 (Influenza Vaccines)
0 (Vaccines, Inactivated)
1HG84L3525 (Formaldehyde)
تواريخ الأحداث: Date Created: 20190216 Date Completed: 20200629 Latest Revision: 20221121
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7115651
DOI: 10.1016/j.vaccine.2019.01.086
PMID: 30765167
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-2518
DOI:10.1016/j.vaccine.2019.01.086